Literature DB >> 9094801

Seroprevalence of HIV infection in childbearing women in Nova Scotia.

B L Johnston1, D A Haase, B A Armson, S H Lee, K Manley, P Hazell.   

Abstract

OBJECTIVE: To determine the prevalence of HIV-1 infection in childbearing women in Nova Scotia.
DESIGN: An anonymous, unlinked seroprevalence study using "leftover" cord bloods. The study was done in 2 stages: I-Halifax Co. women delivering between February 1, 1992 and December 31, 1993; II-non-Halifax Co. women delivering between November 15, 1993 and December 15, 1994.
RESULTS: Of 9,115 deliveries during stage I and 5,515 during stage II, specimens were tested from 8,864 (97.2%) and 5,219 (95%) respectively. Halifax Co. women were older, more often married and more often reported a STD than the non-Halifax Co. participants with 20% under age 20 reporting a history of STD. There was one EIA and WB positive result among Halifax Co. women (seroprevalence 1/10,000; 95% CI 0.03-6.29) and one EIA positive, WB indeterminant result among non-Halifax Co. women (seroprevalence 0/10,000; 95% CI 0-5.7).
CONCLUSION: There is a low prevalence of HIV infection among Nova Scotia childbearing women. However, a substantial number, especially those < age 20, reported a history of STD.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9094801

Source DB:  PubMed          Journal:  Can J Public Health        ISSN: 0008-4263


  2 in total

1.  The influence of prevalence and policy on the likelihood that a physician will offer HIV screening in pregnancy.

Authors:  Kathleen Steel O'Connor; Susan E MacDonald; Lisa Hartling; Rachelle M Seguin; Hussein Hollands; David L Mowat; John R Hoey; Richard Massé; Michael L Rekart
Journal:  Can J Public Health       Date:  2002 Jan-Feb

2.  Prenatal Screening for HIV in Nova Scotia: Survey of Postpartum Women and Audit of Current Prenatal Screening Practices.

Authors:  Mark Downing; Laura Youden; Beth A Halperin; Heather Scott; Bruce Smith; Scott A Halperin
Journal:  Can J Infect Dis Med Microbiol       Date:  2006-07       Impact factor: 2.471

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.